California 2017-2018 Regular Session

California Assembly Bill AB175

Introduced
1/17/17  
Introduced
1/17/17  
Refer
3/27/17  
Refer
3/27/17  
Report Pass
4/18/17  
Refer
4/18/17  
Refer
4/18/17  
Report Pass
4/26/17  
Report Pass
4/26/17  
Refer
4/26/17  
Refer
4/26/17  
Refer
5/3/17  
Refer
5/3/17  
Report Pass
5/26/17  
Report Pass
5/26/17  
Engrossed
5/31/17  
Engrossed
5/31/17  
Refer
6/1/17  
Refer
6/1/17  
Refer
6/14/17  
Report Pass
6/27/17  
Report Pass
6/27/17  
Refer
6/27/17  
Report Pass
7/13/17  
Report Pass
7/13/17  
Refer
7/13/17  
Report Pass
7/19/17  
Report Pass
7/19/17  
Refer
7/19/17  
Refer
7/19/17  
Refer
8/21/17  

Caption

Cannabis marketing: packaging and labeling.

Impact

The implementation of this bill will provide a structured approval pathway for the marketing of edible cannabis products, enhancing safety standards for consumers. This aligns with the broader objectives of existing cannabis legislation in California aimed at fostering a responsible and safe cannabis market. By requiring compliance checks for packaging, the bill seeks to mitigate risks associated with accidental ingestion by children, thus reinforcing public health initiatives and safety regulations surrounding cannabis use.

Summary

Assembly Bill 175, introduced by Assembly Member Chau, relates to the regulation of edible marijuana products in California. The bill mandates that manufacturers submit the packaging and labeling of edible cannabis products to the State Department of Public Health for approval before they can be introduced into commerce. This process aims to ensure that all packaging meets specific safety standards outlined in the Control, Regulate and Tax Adult Use of Marijuana Act (AUMA), specifically emphasizing child resistance and the avoidance of appealing designs that may attract children. Moreover, the Department is authorized to charge manufacturers a fee for this service, which is capped at the costs associated with administering the approval process.

Sentiment

Overall, the sentiment surrounding AB 175 appears to be supportive among legislators who advocate for stricter safety measures in the cannabis industry. The emphasis on child safety resonates well with public health advocates and regulators. However, some critics may raise concerns about the potential financial burden the approval fees could impose on smaller manufacturers, which might deter market entry or innovation within that segment of the cannabis industry.

Contention

Notable points of contention may arise concerning the fees associated with the compliance process and the timeframes for approval set within the bill. Although proactive measures for consumer safety are generally supported, discussions around the financial implications and regulatory burden on manufacturers reflect a tension between safety interests and industry growth. Moreover, the specified compliance process may be debated on how effectively it balances regulation without stifling business operations or access to the market, particularly for smaller businesses.

Companion Bills

No companion bills found.

Similar Bills

CA AB1627

Clinical laboratories: certified phlebotomy technicians: blood withdrawal.

CA AB350

Cannabis edibles: appealing to children.

CA AB64

Cannabis: licensure and regulation.

CA AB823

Edible cannabis products: labeling.

CA AB2520

California Illegal Cannabis Task Force.

CA AB110

In-home supportive services provider wages: emergency caregiver payments for foster care: civil immigration detainees: recording fees.

CA SB94

Cannabis: medicinal and adult use.

CA SB1326

Cannabis: interstate agreements.